NewAmsterdam Pharma Company N.V. (NAMS) Operating cash flow 2021–2025
NewAmsterdam Pharma Company N.V. (NAMS) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$147.8MFY2025 · since FY2021: -$29.5M → -$147.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$147.8M | +6.8% |
| FY2024 | -$158.6M | -12.3% |
| FY2023 | -$141.2M | -1424.1% |
| FY2022 | $10.7M | +136.1% |
| FY2021 | -$29.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMS financial trends
NAMS RevenueNAMS Net incomeNAMS Net marginNAMS Gross profitNAMS Gross marginNAMS Operating incomeNAMS Operating marginNAMS Free cash flowNAMS Capital expendituresNAMS Return on equityNAMS Stock buybacksNAMS Dividends paidNAMS Total assetsNAMS Total liabilitiesNAMS Shareholders’ equityNAMS overview →